PriceTargets.com logo

NanoString Technologies - NSTG Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $7.63
  • Forecasted Upside: ∞
  • Number of Analysts: 6
  • Breakdown:
  • 0 Sell Ratings
  • 4 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
$0.00 As of 02/14/2024 12:59 AM ET
+0 (0.00%)
Get New NanoString Technologies Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for NSTG and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for NSTG

Analyst Price Target is $7.63
▲ +∞ Upside Potential
This price target is based on 6 analysts offering 12 month price targets for NanoString Technologies in the last 3 months. The average price target is $7.63, with a high forecast of $10.00 and a low forecast of $2.50. The average price target represents a ∞ upside from the last price of $0.00.

This chart shows the closing price for NSTG for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Hold

The current consensus among 6 investment analysts is to hold stock in NanoString Technologies. This Hold consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 2 buy ratings
  • 4 hold ratings
  • 0 sell ratings
Ratings as of
11/1/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 4 hold ratings
  • 0 sell ratings
Ratings as of
1/30/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 4 hold ratings
  • 0 sell ratings
Ratings as of
4/30/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 4 hold ratings
  • 0 sell ratings
Ratings as of
7/29/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 4 hold ratings
  • 0 sell ratings
Ratings as of
10/27/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 4 hold ratings
  • 0 sell ratings
Ratings as of
1/25/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 4 hold ratings
  • 0 sell ratings
Ratings as of
3/25/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 4 hold ratings
  • 0 sell ratings
Ratings as of
4/24/2024

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 4 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/27/2023JPMorgan Chase & Co.DowngradeOverweight ➝ NeutralLow
11/21/2023Robert W. BairdDowngradeOutperform ➝ NeutralLow
11/20/2023TD CowenReiterated RatingOutperform ➝ Market PerformLow
10/24/2023Morgan StanleyLower TargetEqual Weight ➝ Equal Weight$14.00 ➝ $8.00Low
10/12/2023UBS GroupLower TargetBuy ➝ Buy$7.00 ➝ $2.50Low
9/19/2023Canaccord Genuity GroupReiterated RatingBuy ➝ Buy$10.00Low
8/7/2023Morgan StanleyLower TargetEqual Weight ➝ Equal Weight$15.00 ➝ $14.00Low
8/4/2023Robert W. BairdLower TargetOutperform ➝ Outperform$13.00 ➝ $10.00Low
3/2/2023Morgan StanleyLower TargetEqual Weight$17.00 ➝ $16.00Low
2/2/2023UBS GroupInitiated CoverageBuy$15.00Low
11/10/2022Canaccord Genuity GroupLower Target$30.00 ➝ $14.00Low
11/9/2022Morgan StanleyLower TargetEqual Weight$28.00 ➝ $17.00Low
11/8/2022CowenLower TargetOutperform$31.00 ➝ $24.00Low
11/8/2022CowenLower TargetOutperform$31.00 ➝ $24.00Low
11/8/2022Robert W. BairdLower TargetOutperform$21.00 ➝ $14.00Low
8/9/2022CowenLower Target$31.00Low
8/8/2022Morgan StanleyLower TargetEqual Weight$30.00 ➝ $28.00Low
8/5/2022Robert W. BairdLower Target$30.00 ➝ $21.00Low
7/19/2022CowenSet Target$33.00Low
5/11/2022Robert W. BairdLower Target$35.00 ➝ $30.00High
4/13/2022CowenLower Target$65.00 ➝ $50.00High
4/13/2022Canaccord Genuity GroupLower TargetBuy$50.00 ➝ $37.00High
4/13/2022CowenLower Target$65.00 ➝ $50.00High
4/13/2022Robert W. BairdLower Target$51.00 ➝ $35.00High
3/24/2022Canaccord Genuity GroupInitiated CoverageBuy$50.00Medium
3/2/2022JPMorgan Chase & Co.Lower TargetOverweight$85.00 ➝ $70.00Medium
3/2/2022Robert W. BairdLower Target$60.00 ➝ $51.00High
11/10/2021Robert W. BairdLower TargetOutperform$71.00 ➝ $60.00High
10/14/2021CowenLower TargetOutperform$75.00 ➝ $65.00Medium
5/11/2021Morgan StanleyLower TargetEqual Weight$70.00 ➝ $65.00Low
3/3/2021Morgan StanleyBoost TargetEqual Weight$55.00 ➝ $70.00High
3/2/2021JPMorgan Chase & Co.Boost TargetOverweight$75.00 ➝ $80.00Medium
3/2/2021Robert W. BairdBoost TargetOutperform$70.00 ➝ $78.00Medium
1/11/2021Robert W. BairdBoost TargetOutperform$60.00 ➝ $70.00High
1/6/2021CowenUpgradeMarket Perform ➝ Outperform$75.00N/A
12/3/2020Morgan StanleyBoost TargetEqual Weight$44.00 ➝ $55.00Low
12/2/2020JPMorgan Chase & Co.Boost Target$45.00 ➝ $60.00Low
12/2/2020Robert W. BairdBoost TargetOutperform$33.00 ➝ $44.00High
9/9/2020Morgan StanleyInitiated CoverageEqual Weight$43.00High
8/11/2020UBS GroupBoost TargetBuy$38.00 ➝ $40.00High
5/11/2020Robert W. BairdBoost TargetOutperform$29.00 ➝ $34.00High
4/28/2020UBS GroupLower TargetBuy$40.00 ➝ $38.00High
4/7/2020Robert W. BairdLower TargetOutperform$35.00 ➝ $29.00Medium
4/2/2020Stifel NicolausLower TargetBuy$38.00 ➝ $35.00Low
11/14/2019Stifel NicolausInitiated CoverageBuy$28.00Low
(Data available from 4/25/2019 forward)

News Sentiment Rating

-0.20 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 4 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/28/2023
  • 1 very positive mentions
  • 5 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
10/28/2023
  • 4 very positive mentions
  • 7 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
Mentions as of
11/27/2023
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/27/2023
  • 0 very positive mentions
  • 3 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
1/26/2024
  • 2 very positive mentions
  • 11 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
2/25/2024
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/26/2024
  • 0 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
4/25/2024

Current Sentiment

  • 0 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 1 very negative mentions

Recent Stories by Sentiment

Very Negative

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

  • No very positive mentions tracked during this time.
NanoString Technologies logo
NanoString Technologies, Inc. develops, manufactures, and sells technology for scientific and clinical information in the fields of genomics and proteomics in the Americas, Europe, the Middle East, and the Asia Pacific. The company offers nCounter Analysis System, an automated, multi-application, digital detection, and counting system. It provides nCounter Pro and FLEX systems that include Prep Station, an automated liquid handling component that processes and prepares samples for data collection; and nCounter Digital Analyzer, which collects data from samples by taking images of the immobilized fluorescent reporters in the sample cartridge and processing the data into output files. The company also offers nCounter SPRINT Profiler, an instrument that provides liquid handling steps and the digital analysis through use of a microfluidic cartridge; and nSolver Analysis Software, a data analysis program that enables researchers to check, normalize, and analyze their data. In addition, it provides custom CodeSets; panels with oncology, immunology and infectious disease, and neuroscience applications. Further, the company offers Master Kits, cartridges, ancillary reagents, tips and reagent plates to setup and process samples in instruments; and Prosigna in vitro diagnostic kits. The company is also developing GeoMx DSP system to enable the field of spatial biology. It has collaboration with Lam Research Corporation for the development of NGS sequencing platform and related assays; and Parker Institute for Cancer Immunotherapy to develop CAR-T regimens that enhances patient outcomes for various types of cancer, as well as collaboration with Stanford Medicine, Acrobat Genomics, and Illumina Accelerator to discover new drug targets for gene editing-based therapeutics. NanoString Technologies, Inc. was incorporated in 2003 and is headquartered in Seattle, Washington. On February 4, 2024, NanoString Technologies, Inc., along with its affiliates, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.
Read More

Today's Range

Now: N/A

50 Day Range

MA: $0.36
Low: $0.05
High: $0.80

52 Week Range

Now: N/A

Volume

23,061,200 shs

Average Volume

34,541,648 shs

Market Capitalization

$5.07 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.24

Frequently Asked Questions

What sell-side analysts currently cover shares of NanoString Technologies?

The following equities research analysts have issued reports on NanoString Technologies in the last year: Canaccord Genuity Group Inc., JPMorgan Chase & Co., Morgan Stanley, Robert W. Baird, StockNews.com, TD Cowen, and UBS Group AG.
View the latest analyst ratings for NSTG.

What is the current price target for NanoString Technologies?

4 Wall Street analysts have set twelve-month price targets for NanoString Technologies in the last year. Their average twelve-month price target is $7.63. Robert W. Baird has the highest price target set, predicting NSTG will reach $10.00 in the next twelve months. UBS Group AG has the lowest price target set, forecasting a price of $2.50 for NanoString Technologies in the next year.
View the latest price targets for NSTG.

What is the current consensus analyst rating for NanoString Technologies?

NanoString Technologies currently has 4 hold ratings and 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in NSTG, but not buy more shares or sell existing shares.
View the latest ratings for NSTG.

What other companies compete with NanoString Technologies?

Other companies that are similar to NanoString Technologies include Silo Pharma, Palisade Bio, Acutus Medical, Venus Concept and Alzamend Neuro. Learn More about companies similar to NanoString Technologies.

How do I contact NanoString Technologies' investor relations team?

NanoString Technologies' physical mailing address is 530 FAIRVIEW AVENUE NORTH SUITE 2000, SEATTLE WA, 98109. The biotechnology company's listed phone number is (888) 358-6266 and its investor relations email address is [email protected]. The official website for NanoString Technologies is www.nanostring.com. Learn More about contacing NanoString Technologies investor relations.